Article
Use of hydroxyurea in children with sickle cell disease: what comes next?
Seminars in hematology - 1 Jul 1997
Ohene-Frempong K, Smith-Whitley K
Abstract excerpt
Hydroxyurea (HU) is the first drug that, under well-organized clinical trials, has shown the potential for altering significantly the clinical severity of sickle cell disease (SCD). The placebo-controlled trial of HU in adult SS hemoglobinopathy patients (the Multicenter Study of Hydroxyurea in Sickle Cell Anemia) reported in May 1995 that HU therapy reduced significantly the frequencies of severe pain episodes,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.